However, since neither AKT or STAT inhibitors have been FDA-approved for clinical use in MM, identifying other targetable PKs crucial in MM tumorigenesis might contribute to the development of novel anti-MM compounds. This evidence concerns the gene AKT1 and Miyoshi myopathy.